Improved Metabolic Control After 12-Week Dietary Intervention with Low Glycaemic Isomalt in Patients with Type 2 Diabetes Mellitus

Abstract

The polyol isomalt (Palatinit^®) is a very low glycaemic sugar replacer. The effect of food supplemented with isomalt instead of higher glycaemic ingredients like sucrose and/or starch hydrolysates on metabolic control in patients with type 2 diabetes was examined in this open study. Thirty-three patients with type 2 diabetes received a diet with foods containing 30 g/d isomalt instead of higher-glycaemic carbohydrates for 12 weeks. Metformin and/or thiazolidindiones were the only concomitant oral antidiabetics allowed during the study. Otherwise, the participants maintained their usual diet during the test phase, but were instructed to refrain from additional sweetened foods. Before start, after 6 weeks and 12 weeks (completion of the study), blood samples were taken and analysed for clinical routine parameters, metabolic, and risk markers. Thirty-one patients completed the study. The test diet was well accepted and tolerated. After 12 weeks, significant reductions were observed for: glycosylated haemoglobin, fructosamine, fasting blood glucose, insulin, proinsulin, C-peptide, insulin resistance (HOMA-IR), and oxidised LDL (an atherosclerosis risk factor). In addition, significant lower nonesterified fatty acid concentrations were found in female participants. Routine blood measurements and blood lipids remained unchanged. The substitution of glycaemic ingredients by isomalt and the consequent on reduction of the glycaemic load within otherwise unchanged diet was accompanied by significant improvement in the metabolic control of diabetes. The present study is in agreement with findings of previous reported studies in human subjects demonstrating beneficial effects of low glycaemic diets on glucose metabolism in patients with diabetes mellitus type 2.

glycaemic index - glycaemic load - carbohydrate metabolism

References

• 1 Yach D, Stuckler D, Brownell KD. Epidemiology and economic consequences of the global epidemics of obesity and diabetes.  Nat Med. 2006;  12 62-66
• 2 Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.  Nature. 2001;  414 782-787
• 3 Dickinson S, Brand-Miller J. Glycemic index, postprandial glycemia and cardiovascular disease.  Curr Opin Lipidol. 2005;  16 69-75
• 4 Ludwig DS, Eckel HE. The glycemic index at 20 y.  Am J Clin Nutr. 2002;  76 S264-S265
• 5 Livesey G, Buss D, Coussement P, Edwards DG, Howlett J, Jonas DA, Kleiner JE, Müller D, Sentko A. Suitability of traditional energy values for novel foods and food ingredients.  Food Control. 2000;  11 249-289
• 6 Gehring F, Karle EJ. Sweetening agent, Palatinit under specific consideration as to microbiological and caries-prophylactic aspects.  Z Ernährungswiss. 1981;  20 96-106
• 7 Langkilde AM, Andersson H, Schweizer TF, Wursch P. Digestion and absorption of sorbitol, maltitol and isomalt from small bowel.  A study in ileostomy subjects. Eur J Clin Nutr. 1994;  48 768-775
• 8 Life Science Research Office .The Evaluation of the Energy of Certain Sugar Alcohols used as Food Ingredients. Bethesda, MD: Life Science Research Office, Federation of the American Society for Experimental Biology 1994
• 9 Livesey G. Health potential of polyols as sugar replacers, with emphasis on low glyceamic properties.  Nutr Res Rev. 2003;  16 163-289
• 10 Bär A. Factorial calculation model fort he estimation of the physiological caloric value of polyols. In: Hosoxa N, ed Proceedings of the International Symposium on Caloric Evaluation of Carbohydrates. Tokyo: Research Foundation for Sugar Metabolism 1990: 209-257
• 11 Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index and glycemic load values: 2008.  Diabetes Care. 2008;  31 2281-2283
• 12 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 13 Gostner A, Schäffer V, Theis S, Menzel T, Lührs H, Melcher R, Schauber J, Kudlich T, Dusel G, Dorbath D, Kozianowski G, Scheppach W. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers.  Br J Nutr. 2005;  94 575-581
• 14 Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials.  Diabetes Care. 2003;  26 2261-2267
• 15 Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vortser HH. Meta-analysis of the health effects of using the glycemic index in meal-planning.  Br J Nutr. 2004;  92 367-381
• 16 Livesey G, Taylor R, Hulshof T, Howlett J. Glycemic response and health – a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes.  Am J Clin Nutr. 2008;  87 ((Suppl)) 258S-268S
• 17 Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.  Postgrad Med J. 2005;  81 1-6
• 18 Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus.  Am J Cardiol. 2001;  88 9H-15H
• 19 Gokulakrishnan K, Deepa R, Velmurugan K, Ravikumar R, Karkuzhali K, Mohan V. Oxidised low-density lipoprotein and intimal medial thickness in subjects with glucose intolerance: the Chennai Urban Rural Epidemiology Study-25.  Metabolism. 2007;  56 245-250
• 20 Hawkins M, Tonelli J, Kishore P, Stein D, Ragucci E, Gitig A, Reddy K. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes.  Diabetes. 2003;  52 2748-2758
• 21 Pilz S, Scharnagl H, Tiran B, Seelhorst U, Wellnitz B, Boehm BO, Schaefer JR, Marz W. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease.  J Clin Endocrinol Metab. 2006;  91 2542-2547
• 22 Rizkalla SW, Taghrid L, Laromiguiere M, Huet D, Boillot J, Rigoir A, Elgrably F, Slama G. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial.  Diabetes Care. 2004;  27 1866-1872
• 23 Ren S, Lee H, Hu L, Lu L, Shen GX. Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.  J Clin Endocrinol Metab. 2002;  87 286-291
• 24 Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events.  Thrombosis and haemostasis. 1997;  78 656-660
• 25 Clausen P, Feldt-Rassmussen B, Jensen G, Jensen JS. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study.  Clin Sci. 1999;  97 37-43
• 26 Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle.  Nutr Metab (Lond). 2004;  1 10
• 27 Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.  J Clin Invest. 2006;  116 1784-1792
• 28 Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.  Eur Heart J. 2005;  26 1640-1646
• 29 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
• 30 Qi L, Meigs JB, Liu S, Manson JE, Mantzoros C, Hu FB. Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes.  Diabetes Care. 2006;  29 1501-1505
• 31 Anderlova K, Kremen J, Dolezalova R, Housova J, Haluzikova D, Kunesova M, Haluzik M. The influence of very-low-calorie diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obsese women.  Physiol Res. 2006;  55 277-283
• 32 Bouche C, Rizkalla SW, Luo J, Vidal H, Veronese A, Pacher N, Fouquet C, Lang V, Slama G. Five-week, low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men.  Diabetes Care. 2002;  25 822-828
• 33 McMillan-Price J, Petocz P, Atkinson F, O’Neill K, Samman S, Steinbeck K, Caterson I, Brand-Miller J. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial.  Arch Intern Med. 2006;  166 1466-1475
• 34 Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced-glycemic load diet in the treatment of adolescent obesity.  Arch Pediatr Adolesc Med. 2003;  157 773-779
• 35 Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes.  Diabetes Obes Metab. 2000;  2 121-129
• 36 Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetes patients.  Arch Intern Med. 1987;  147 749-753
• 37 Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SS, Musey VC, Siddig YK, Phillips LS. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus.  Arch Intern Med. 1990;  150 803-806
• 38 Blonk MC, Jacobs MA, Biesheuvel EH, Weeda-Mannak WL, Heine RJ. Influences on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training.  Diabet Med. 1994;  11 449-457

Correspondence